CD45 antibody | YKIX716.13

100% Secure


Rat anti Dog CD45:Alexa Fluor® 488

Rat anti Dog CD45:Alexa Fluor® 647

Rat anti Dog CD45:APC

Rat anti Dog CD45:Biotin

Rat anti Dog CD45:FITC

Rat anti Dog CD45

Rat anti Dog CD45:RPE

Product Type
Monoclonal Antibody
Clone
YKIX716.13
Isotype
IgG2b
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
MCA1042A488 F 100 Tests/1ml
MCA1042A647 F 100 Tests/1ml
MCA1042APC F 100 Tests
MCA1042B F 0.1 mg
MCA1042F F 0.1 mg
MCA1042GA F IP 0.1 mg
MCA1042PE F 100 Tests
Rat anti Dog CD45 antibody, clone YKIX716.13 recognizes canine CD45 also known as leukocyte common antigen lustered as Canine CD45 in the First Canine Leukocyte Antigen Workshop (CLAW). Clone YKIX 716.13: immunoprecipitates an antigen of ~180/200 kDa from Con-A blasts (Cobbold et al. 1994). CD45 is expressed on all leukocytes in canine peripheral blood. Rat anti Dog CD45 antibody, clone YKIX716.13 reacts with CD45 on all outbred mongrels and beagles tested and may be against CD45RB isoform.

Product Details

Target Species
Dog
Product Form
Purified IgG conjugated to Alexa Fluor® 488 - liquid
Product Form
Purified IgG conjugated to Alexa Fluor® 647 - liquid
Product Form
Purified IgG conjugated to Allophycocyanin (APC) - lyophilised
Product Form
Purified IgG conjugated to Biotin - liquid
Product Form
Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
Product Form
Purified IgG - liquid
Product Form
Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
Reconstitution
Reconstitute with 1ml distilled water
Reconstitution
Reconstitute with 1ml distilled water
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
5%Sucrose
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
5%Sucrose
Carrier Free
Yes
Immunogen
Canine thymocytes.
Approx. Protein Concentrations
IgG concentration 0.05 mg/ml
Approx. Protein Concentrations
IgG concentration 0.05 mg/ml
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Fusion Partners
Spleen cells from immunised DA rats were fused with cells of the Y3/Ag1.2.3 rat myeloma cell line.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
12 months from date of reconstitution.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
12 months from date of reconstitution.

More Information

Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Regulatory
For research purposes only

Applications of CD45 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat 1/5
Flow Cytometry Neat 1/5
Flow Cytometry Neat
Flow Cytometry Neat
Flow Cytometry Neat 1/5
Flow Cytometry 1/50 1/100
Immunoprecipitation
Flow Cytometry Neat 1/10
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own systems with appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 100ul whole blood.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells in 100ul.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) STAR131A 1 ml C E P WB
Goat anti Rat IgG:Biotin (Mouse Adsorbed) STAR131B 0.5 mg C E IF P WB
Rabbit F(ab')2 anti Rat IgG:Dylight®800 STAR16D800GA 0.1 mg F IF WB
Rabbit F(ab')2 anti Rat IgG:FITC STAR17B 1 mg F
Rabbit F(ab')2 anti Rat IgG:HRP STAR21B 1 mg C E P RE
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) STAR69 0.5 ml F
Goat anti Rat IgG:DyLight®649 (Mouse Adsorbed) STAR71D649GA 0.1 mg F IF
Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) STAR71D800GA 0.1 mg F IF WB
Goat anti Rat IgG:HRP (Mouse Adsorbed) STAR72 0.5 mg C E P
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) STAR73 0.5 ml F

Negative Isotype Controls Available

Description Product Code Pack Size Applications List Price Quantity
Rat IgG2b Negative Control:Alexa Fluor® 647 MCA6006A647 100 Tests/1ml F
Rat IgG2b Negative Control:APC MCA6006APC 100 Tests F
Rat IgG2b Negative Control:Biotin MCA6006B 0.1 mg F
Rat IgG2b Negative Control:FITC MCA6006F 0.1 mg F
Rat IgG2b Negative Control MCA6006GA 0.1 mg F
Rat IgG2b Negative Control:RPE MCA6006PE 100 Tests F

Application Based External Images

Flow Cytometry

Immunohistology - Frozen

Product Specific References

References for CD45 antibody

  1. Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
    Tissue Antigens. 43 (3): 137-54.
  2. Reis, A.B. et al (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi.
    Clin Exp Immunol.146: 303-11.
  3. Stein, V.M. et al. (2008) Immunophenotypical characterization of monocytes in canine distemper virus infection.
    Vet Microbiol. 131:237-46.
  4. Sanchez, M.A. et al. (2004) Organ-specific immunity in canine visceral leishmaniasis: analysis of symptomatic and asymptomatic dogs naturally infected with Leishmania chagasi.
    Am J Trop Med Hyg. 70: 618-24.
  5. Modiano,J.F. and Helfand,S.C. (2011) Early detection of hemangiosarcoma and angiosarcoma
    Patent Application No.11/662529
  6. Tominaga, M. et al. (2010) Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma.
    J Vet Diagn Invest. 22: 438-41.
  7. Zentek, J. et al. (2002) Morphology and immunopathology of the small and large intestine in dogs with nonspecific dietary sensitivity.
    J Nutr. 132: 1652S-4S.
  8. Hunter, M.J. et al. (2011) Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression.
    Mol Ther. 19: 113-21.
  9. Comazzi, S. et al. (2006) Flow cytometric patterns in blood from dogs with non-neoplastic and neoplastic hematologic diseases using double labeling for CD18 and CD45.
    Vet Clin Pathol. 35: 47-54.
  10. Giantin, M. et al. (2013) Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein expression in canine leukemia: might c-KIT represent a therapeutic target?
    Vet Immunol Immunopathol. 152: 325-32.
  11. Trichler, S.A. et al. (2013) Ultra-pure platelet isolation from canine whole blood.
    BMC Vet Res. 9: 144.
  12. Aresu, L. et al. (2014) VEGF and MMP-9: biomarkers for canine lymphoma.
    Vet Comp Oncol. 12: 29-36.
  13. Salinas Tejedor, L. et al. (2015) Mesenchymal stem cells do not exert direct beneficial effects on CNS remyelination in the absence of the peripheral immune system.
    Brain Behav Immun. pii: S0889-1591(15)00233-0.
  14. Muir, P. et al. (2016) Autologous Bone Marrow-Derived Mesenchymal Stem Cells Modulate Molecular Markers of Inflammation in Dogs with Cruciate Ligament Rupture.
    PLoS One. 11 (8): e0159095.
  15. Poggi, A. et al. (2017) Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma.
    Vet Comp Oncol. 15 (2): 431-440.
  16. Zeira, O. et al. (2015) Adult autologous mesenchymal stem cells for the treatment of suspected non-infectious inflammatory diseases of the canine central nervous system: safety, feasibility and preliminary clinical findings.
    J Neuroinflammation. 12: 181.
  17. Gelain, M.E. et al. (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood.
    Vet Immunol Immunopathol. 159 (1-2): 91-6.
  18. Michael, H.T. et al. (2013) Isolation and characterization of canine natural killer cells.
    Vet Immunol Immunopathol. 155 (3): 211-7.
  19. Nishimura, T. et al. (2017) Feeder-independent canine induced pluripotent stem cells maintained under serum-free conditions.
    Mol Reprod Dev. 84 (4): 329-339.
  20. Bonnefont-Rebeix, C. et al. (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology.
    Immunobiology. 221 (1): 12-22.
  21. Bearden, R.N. et al. (2017) In-vitro characterization of canine multipotent stromal cells isolated from synovium, bone marrow, and adipose tissue: a donor-matched comparative study.
    Stem Cell Res Ther. 8 (1): 218.
  22. Lee, S.H. et al. (2016) Impact of local injection of brain-derived neurotrophic factor-expressing mesenchymal stromal cells (MSCs) combined with intravenous MSC delivery in a canine model of chronic spinal cord injury.
    Cytotherapy. Oct 28 [Epub ahead of print].